Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”).

Click here to discover the nuances of Insulet with our detailed analytical report. NasdaqGS:PODD Revenue & Expenses Breakdown as at Mar 2025 Insulet (NasdaqGS:PODD) has rewarded its shareholders ...

Insulet (PODD) reported $597.5 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 17.2%. EPS of $1.15 for the same period compares to $1.40 a year ago.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Shares of Insulet Co. (NASDAQ:PODD – Get Free Report) have received an average rating of “Moderate Buy” from the seventeen research firms that are currently covering the company, MarketBeat ...